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Purpose of the review 
Examine the role of ECMO as potential therapeutic option for severe cases of ARDS. 
 
Recent findings 
Use of ECMO to treat acute respiratory failure dramatically increased.  Factors that 
may explain this increase in the use of ECMO are H1N1 pandemic influenza, results 
of recent clinical trials and not lastly the technological development and 
consequently the commercial pressure of the industry.  Under these circumstances 
clinicians urgently need clinical trials and formal indication, contra-indication and 
rules for implementation to provide reproducible results. 
 
Summary 
Guidelines from the Extracorporeal Life Support Organization (ELSO) still indicate 
ECMO for acute severe pulmonary failure potentially reversible and unresponsive to 
conventional management.  The new definition of ARDS (Berlin definition) 
addresses clinicians to the best treatment options in respect of the severity of illness 
and allocate ECMO as a potential therapeutic option for patients with severe ARDS 
and a P/F ration lower than 100 and proposed that the indication of ECMO may be 
shifted from the treatment of choice for refractory hypoxemia to the treatment of 
choice to minimize ventilator induced lung injury.  
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INTRODUCTION 
In the recent years, the use of extra-corporeal membrane oxygenation (ECMO) 
to treat acute respiratory failure has dramatically increased even if evidence of 
benefit on mortality from large randomized clinical trial is still lacking.[1] Hirshberg 
and coworkers showed that in the US from 1996 to 2006 the use of ECMO stably 
remained around 100 cases a year, but in 2009 it increased dramatically up to 400 
patients per year.[2**] Factors that may explain this increase in the use of ECMO are 
(a) the H1N1 pandemic influenza [1]; (b) the publication of the results of a recent 
randomized clinical trial [3]; (c) the technological development of ECMO devices. 
[4, 5]. 
During the H1N1 pandemic, hundreds of ARDS patients worldwide received 
ECMO. The Australian and New Zealand network reported 68 patients with 
suspected H1N1-associated ARDS treated with ECMO with 71% of survival to ICU 
discharge.[6] The Italian ECMO network reported 60 patients with a survival of 77% 
in patients receiving ECMO within 7 days from the onset of mechanical 
ventilation.[7] Conventionally, patients with ARDS need ECMO for a short-term 
respiratory or respiratory-circulatory associated support as a therapeutic option that 
may restore oxygenation when “conventional” supportive therapy fails.  A more 
extended use would indicate ECMO as a total or partial alternative to mechanical 
ventilation to minimize ventilator-induced lung injury (VILI). 
In the present chapter we will (a) describe the basic technological and 
physiological principles of ECMO; (b) discuss the current “conventional” indication 
as supportive therapy for hypoxemia refractory to standard treatments; (c) examine 
the possible “non-conventional” use of ECMO as partial or total alternative to 
mechanical ventilation. 
 
What is ECMO? 
Basic characteristics of extra-corporeal devices are described in details 
somewhere else. [8-10] ECMO-devices conventionally used in patients with ARDS 
require vascular catheters with high diameter and wire-reinforced thin walled to 
minimize flow resistances and reduces the incidence of kinking.  The modern 
oxygenators are made with polymethylpentene fibers that present low resistance, 
lesser incidence of thrombocytopenia and lower consumption of blood products and 
are connected to an oxygen source.  These new devices are capable of oxygen 
delivery (3ml/Kg/min) and CO2 removal (3-6 ml/Kg/min) equal to the normal 
metabolism of the patient.[5] In general with ECMO, blood flow and FiO2 are the 
main determinant of arterial oxygenation while CO2 elimination depends on sweep 
gas flow through the oxygenator. Other factors that influence oxygen transfer are 
blood-oxygen saturation in the ECMO drainage cannula, haemoglobin concentration 
and intrinsic membrane-oxygenator properties, which depend on exchange-
membrane surface and O2 diffusibility through hollow microfibers. In this case total 
support devices are able to completely supply the physiological blood gas exchanges 
normally performed by the native lungs. Blood should be re-infused in the aorta (in 
case of arterial-venous bypass) or in the right atrium (for veno-venous bypass) to 
obtain respectively cardiac and respiratory or only lung function support. It is also 
necessary to use high heparin doses and elevated volumes of priming for the device 
for proper function.  A ratio between ECMO flow and cardiac output > 60 % can be 
constantly associated with adequate blood oxygenation, oxygen transport and 
delivery.[11] The ECMO device can be “undersized” to remove CO2 (partial 
extracorporeal support: ECCO2-R).  The ability to remove CO2 correlates with the 
level of blood flow level, the characteristics of membrane lung, the sweep gas rate 
and the patient’s basal carbon dioxide production [5, 12, 13]. ECCO2-R may be 
considered as an intermediate level of technical complexity. Small (14-Fr), usually 
double-lumen catheters allow a blood flow of 0.3–0.5 l/min, which is constantly 
guaranteed by a roller non-occlusive pump designed to minimize haemolysis.  Blood 
is driven through an oxygenator membrane, which is connected to an oxygen source 
of 6–8 l/min.  Some devices also include hemofilter in series with the oxygenator, to 
allow the extraction of plasmatic water that is re-infused in the circuit, in order to 
lower haematocrit and to prevent blood clotting. A centrifugal pump, which creates a 
radial flow going through an annular fiber oxygenator, has also been used in other 
veno-venous ECCO2-R systems. This design maximizes the exchange surface and, 
therefore, the device efficiency. Both technological implementations are able to 
remove up to 25% of carbon dioxide production and can transfer no more than 10 
ml/min of oxygen. Low doses of heparin (4–18 IU/min) are necessary to avoid 
clotting occurrence.[12]  
During the extracorporeal procedures, complications may arise from 
malfunction of the device or from patient-related adversities. Technical 
complications occur in 5% of the treated patients and are represented by pump and 
cannula malfunction. Regarding patient-related complications, the most frequent is 
bleeding, which occurs with a frequency of up to 30%, haematological changes 
during extracorporeal support as haemolysis, coagulation problems with clotting in 
the circuit and trombocytopenia due to heparin use or to blood surface exposure. 
 
ECMO as rescue therapy of ARDS 
Acute respiratory distress syndrome (ARDS) is characterized by a 
heterogeneous lung damage with significant variations in severity and consequently 
in survival.  Mortality from severe ARDS in the 1970s was as high as 85–90%, but 
from 2000 it decreased to 20-40%.[14] Refractory hypoxemia, i.e PaO2 < 60 mm Hg 
for at least 1 hour while receiving an FIO2 of 1.0 is rare and a non frequent cause of 
death (15 % of ARDS deaths). Use of ECMO to treat refractory hypoxemia was 
controversial for the last 40 years. In the past, the highly specialized equipment and 
knowledge required to provide ECMO made this technique available only in few 
medical centers.  In the last decade, vast improvements in technology, made ECMO 
simpler, less invasive, more biocompatible, inherently safer and relatively cheaper. 
(Fig.1, 2)  
All these technological advances increased the practice of inter-hospital 
transfer of patients required ECMO: recent reports suggest that the transfer of 
patients with severe hypoxia to specialized centers is becoming a standard practice.  
The CESAR trial is the only published study in the last two decades that 
evaluated modern ECMO practice. The CESAR study shows that an ECMO-based 
management protocol significantly improves survival without severe disability, if 
compared with conventional mechanical ventilation. The absolute risk reduction for 
the primary outcome (death or severe disability) was 16%, which translates to a NNT 
of 6 patients.[17] Major bias of the study are represented by inter-site variations of 
mechanical ventilation strategy (the condition of patients in the conventional arm did 
not get a standardized ventilatory treatment) and the “centre experience” led to an 
improved outcome in patients randomized in the ECMO arm. 
Referral networks of selected intensive care units able to provide advanced 
respiratory care for patients with ARDS, up to extracorporeal membrane 
oxygenation, started with the emergency of H1N1 influenza.[8] In the Italian ECMO 
network experience, clinicians planned two complementary strategies to minimize 
risks associated with patient transport: a) indication to move patients towards 
specialized centers based on a risk anticipation principle: clinical criteria for the 
transfer were chosen to allow the mobilization in advance of the as large as possible 
proportion of patients potentially at risk of severe respiratory deterioration; b) 
identification of precise criteria to place the patients under the responsibility of 
expert teams, able to place ECMO and then provide safe transportation of the patient 
with ECMO towards the referral center. In the 2011 Noah et al. compared in a cohort 
of 80 patients with severe H1N1-related ARDS the hospital mortality of patients 
referred, accepted, and transferred for ECMO with matched patients who were not 
referred for ECMO in the United Kingdom during the H1N1 pandemic in winter 
2009-2010. The hospital mortality rate was 23.7% for ECMO-referred patients vs 
52.5% for non–ECMO-referred patients.[18] A subsequent study from the French 
Research Network identified new factors associated with survival in ECMO patients 
(age, lactate, and plateau pressure). Authors analyzed factors associated with in-ICU 
death in ECMO recipients and the potential benefit of ECMO using a propensity 
score–matched (1:1) cohort analysis.  Mortality was not different between the two 
matched cohorts but authors signaled that 51 ECMO patients who could not be 
matched were younger, had lower PaO2/FIO2 ratio, had higher plateau pressure, but 
also had a lower ICU mortality rate, than the 52 matched ECMO patients (22% vs. 
50%).[19] 
A special warning should be raised for patients with severe ARDS caused by 
sepsis or septic shock with an higher cardiac output and impaired peripheral oxygen 
extraction. In these situations, even ECMO flow up to 6 L/min might not achieve 
adequate blood oxygenation and O2 delivery particularly if the pulmonary gas-
exchange capacity is severely impaired.  When blood oxygenation and SaO2 and O2 
delivery remain low despite maximal ECMO flow, clinicians should consider to 
increase the threshold of blood transfusion to a value of haemoglobin of 10 g/dL. 
 
ECMO TO PREVENT VENTILATOR INDUCED LUNG INJURY 
Mechanical ventilation (MV) is a lifesaving treatment delivered in various 
settings. The thought of artificially inflate the lung with air has been considered and 
mentioned since the ancient Egyptians and in the Bible, as nicely described by Baker 
in his “Artificial respiration, the history of an idea” [20]. Interestingly, the paper that 
provided the first formal description of MV as a clinical tool, anticipated the 
possibility of replacing the function of the lung by extracorporeal means by trying 
“whether the suffering the Blood to circulate through a vessel, so as it may be openly 
exposed to the fresh Air, will not suffice for the life of an animal” [21]. 
VT of 6 ml/kg predicted body weight (PBW) and end-inspiratory plateau 
pressure (PPLAT) of a maximum of 30 cm H2O represent the gold standard of 
mechanical ventilation in ARDS patients [14].  However, it is still unclear whether 
tidal volume as low as 6 mL/kg and plateau pressures <30 cmH2O are safe enough or 
an additional reduction of these threshold would further reduce VILI and improve the 
survival rate. Along this line of research, Terragni and colleagues demonstrated with 
CT scan of the chest that about one third of patients with severe ARDS, although 
ventilated with tidal volumes of 6 mL/kg of predicted body weight, had evidence of 
alveolar overdistension. [22] Accordingly, Hager and colleagues showed that a 
plateau pressure of 30 cmH2O in some patients may not be safe and suggested that 
the lower the plateau pressure the lower the mortality rate [23].  This further 
reduction in VT and Pplat may theoretically be managed by two different kinds of 
extracorporeal support: (a) Extra-Corporeal CO2 Removal (ECCO2-R or partial 
ECMO support) [4, 5]; (b) total ECMO support in which clinician can select the right 
ventilatory setting increasing the blood flow from two liters (to remove total CO2) to 
5-6 liters in cases of severe hypoxemia. [7-10]  
The use of ECMO to “rest the lung” was first tested by Gattinoni and 
coworkers who showed that ECMO was associated to an observed mortality rate of 
51%, significantly lower than what predicted in these patients [24]. Unfortunately, 
the study did not have a control group. Moreover, the authors reported a significant 
incidence of adverse effects, such as blood loss in the circuit, need of blood 
transfusion (~1800 ml per day) and bleeding from the insertion site of the catheters 
of the extracorporeal circuit.  Morris et al. published a randomized clinical trial 
comparing pressure controlled inverse-ratio ventilation with an extracorporeal CO2 
removal technique in patients with ARDS. However, no significant difference in 
survival was found between the mechanical ventilated patients and those treated with 
the extracorporeal CO2 removal strategy [25]. 
More recently, a pumpless extracorporeal technique (interventional Lung 
Assist: iLA NovaLung GmbH, Hechingen, Germany), has been proposed for the 
treatment of patients with critical hypoxia/hypercapnia [26]. A membrane with high 
efficiency in CO2 removal is placed in an artero-venous extracorporeal circuit 
(usually between the femoral artery and the femoral vein). Blood flow is driven by 
the artero-venous pressure gradient through a very low-resistance heparin coated 
circuit and, therefore, it cannot be controlled, but depends only on the hemodynamic 
features of the patient. Moreover, similarly to the ECMO technique, the arterial 
cannulation can induce lower limb ischemia if the use of this device is required for 
prolonged period of time. These limitations may reduce the clinical indication for 
this very promising strategy. The efficacy of a new minimally invasive CO2 removal 
technique using an extracorporeal membrane gas exchanger placed into a veno-
venous pump-driven bypass has been evaluated in severe ARDS patients [27]. The 
main features of this system are a lower blood flow (191–422 ml/min - 5–10% of 
cardiac output), a small neonatal membrane lung (0.33 m2) instead of two large adult 
membrane lung (3 - 4.5 m2 each), the use of smaller (14-French) double-lumen 
catheters, and a relatively small infusion rate of heparin (3–19 IU/kg). This 
minimally invasive CO2 removal technique efficiently and safely contributed to the 
correction of the respiratory acidosis consequent to the significant reduction of tidal 
volume in subjects with severe ARDS, allowing a more protective ventilation 
strategy.  
A recent trial from Bein and coworkers demonstrated the efficacy of 
ventilation with very low tidal volume (<3 ml/kg PBW) combined with a pumpless 
arterial-venous extracorporeal technique device in improving clinical outcome in  
ARDS patients with a PaO2/FIO2 <150. [28*] This trial confirms the feasibility and 
the potential efficacy of a "super protettive" ventilatory strategy that combines  very 
low tidal volume with extracorporeal elimination of carbon dioxide as previously 
reported by Terragni and colleagues in 2009.[12] 
 
CONCLUSIONS 
Successful clinical trials with statistical significance are difficult to perform in 
intensive care patient populations. Involving highly specialized treatments, studies on 
critical care lack of clear definitions and classification of their critical clinical 
conditions.  
Identification of patients with more severe respiratory diseases could be crucial 
to evaluate treatment in more homogeneous populations. For this reason, a revised 
definition of clinical criteria for ARDS, the “Berlin definition”, was recently 
established to classify patients according to their disease severity. [29, 30**] ARDS 
was classified depending on oxygenation as mild, moderate, or severe if 
PaO2/FiO2 was, respectively, between 201 and 300 mm Hg, 101 and 200 mm Hg, or 
100 mm Hg or less, using a minimal PEEP level of 5 cm H2O. Oxygenation criteria 
were well correlated to severity, with a mortality corresponding to 27, 32, and 45% 
in mild, moderate, and severe ARDS.  These news P/F thresholds chosen for the 
different levels of ARDS severity could be helpful in categorizing patients with 
respect to different therapeutic approaches identifying a P/F ratio ≤ 100 mm as main 
entry criteria for trials testing ECMO in severe ARDS.[29] 
The “EOLIA” trial (ECMO to rescue Lung Injury in severe ARDS; 
ClinicalTrials.gov NCT01470703) and the SUPERNOVA trial (A Strategy of 
UltraProtective lung ventilation with Extracorporeal CO2 Removal for New-Onset 
moderate to seVere ARDS; ESICM trial group-registration on going) have been 
designed according to these principles. The former will evaluate the impact of 
ECMO, instituted early after the diagnosis of ARDS not evolving favorably after 3-6 
hours under optimal ventilatory management and maximum medical treatment, on 
the morbidity and mortality associated with this disease, the latter will evaluate 
whether a strategy of enhanced lung-protective (lower tidal volume, lower pressure) 
ventilation, along with control of the ensuing hypercapnia using the latest generation 
ECCO2R devices, will improve clinical outcomes compared with standard-of-care 
lung-protective ventilation in patients with moderate ARDS. 
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Fig.1 
Use of ECMO to treat refractory hypoxemia. 
Patient on V-V ECMO (A) for primary graft failure (PGF) and severe associated 
ARDS, following one-lung transplantation. 
PGF represents a severe form of ischemia-reperfusion lung injury to the lung 
allograft occurring in the early post-transplant period characterized by diffuse 
alveolar opacities (developing within 72 h of transplantation) and an arterial partial 
pressure of oxygen/fraction of inspired oxygen (PaO2/FIO2) ratio of < 100 (beyond 
48 h postoperatively). [15] 
Different value of compliance between the right (transplanted) and the left (native) 
lung needed independent lung ventilation (ILV) with two different ventilatory 
strategies: High-Frequency Oscillatory Ventilation (HFOV) (B) in the transplanted 




Radiographic feature of primary graft failure in severe ARDS patient following one-
lung transplantation. 
A case of Independent High-Frequency Oscillatory Ventilation in the management of 
asymmetric ARDS: right transplanted (T) and the left native lung (N). 
ILV is often applied in asymmetric lung injury because application of tidal inflation 
and PEEP to the heterogeneous lung may overdistend the uninvolved lung and divert 
pulmonary blood flow to the injured lung area, thus worsening ventilation/perfusion 
mismatch.[16] 
KEY POINTS 
1. In the last decade, vast technical improvements in technology have made 
ECMO practice much simpler, less invasive, more biocompatible, inherently 
safer and relatively cheaper.  
2. The advances in technology and clinical practice, especially after the H1N1 
pandemic influenza experience, have convinced clinicians to extend ECMO 
support to others fields such as severe bridge to lung transplant, COPD, 
ARDS combined with intracranial bleeding, asthma, and also to facilitate the 
use of “ultra-protective” MV in severe ARDS (employing VT <6 ml/kg PBW 
and lowering airway pressures) minimizing the risk of VILI. 
3. To date, a standardized selection criteria for patients who will benefit from 
ECMO therapy does not yet exist, a future trial aimed to test a defined 
protocol with clear patient selection criteria and no crossover treatments 
would clarify the validity of ECMO support in ARDS patients.  
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